Objective: To investigate the efficacy of mifepristone in patients with Cushing's syndrome and the incidence of adverse reactions to provide basis for its clinical use.Methods: One case of Cushing's syndrome treated with mifepristone participated by pharmacist was analyzed.Results: Mifepristone could significantly improve hyperlipidemia and the complications of the patient, meanwhile, the risk of hypoglycemia should be paid attention and insulin therapy should be withdrawn timely.Conclusion: Mifepristone can significantly reduce blood glucose levels and improve the appearance of Cushing.At the same time, the level of serum potassium needs close monitoring to avoid the occurrence of hypokalemia.

Objective:To explore the clinical characteristics and prognosis of metastatic sites symptom as the first manifestation in esophageal carcinoma patients with stage T 1 and T 2, and to provide a reference for clinical practice. Methods:The clinical data of 50 esophageal carcinoma patients with stage T 1 and T 2 who had lymph node or distant metastasis as the first symptom in Anyang Tumor Hospital of Henan Province from November 2007 to December 2019 were retrospectively analyzed. Survival analysis was performed by using Kaplan-Meier method. Univariate analysis was performed by using log-rank test. Results:Among 50 patients with esophageal carcinoma, lymph node metastases as the first symptom were found in 42 cases and distant organ metastases as the first symptom were found in 8 cases. The 1-, 3-, 5-year overall survival rates of patients with stage Ⅰ-Ⅱ and stage Ⅲ-Ⅳ were 58.7%, 49.0%, 16.3% and 56.1%, 12.2%, 0, respectively, and there was no statistically significant difference in OS of both groups ( P = 0.094). The 1-, 3-, 5-year overall survival rates of patients with stage N 1 and stage N 2-N 3 were 63.5%, 34.7%, 17.3% and 52.2%, 11.9%, 0, respectively, and there was no statistically significant difference in OS of both groups ( P = 0.083). The 1-, 3-, 5-year overall survival rates were 64.6%, 30.5%, 18.3%, respectively in radiotherapy group and 38.2%, 0, 0, respectively in non-radiotherapy group, and there was a statistically significant difference in OS of both groups ( P = 0.008); the progression-free survival in radiotherapy group was better than that in non-radiotherapy group ( P = 0.028). The 1-, 3-, 5-year overall survival rates were 70.8%, 35.5%, 21.3% and 33.3%, 0, 0 and 35.4%, 0, 0, respectively in concurrent chemoradiotherapy group, radiotherapy group and chemotherapy group, and there was a statistically significant difference in overall survival among three groups ( P = 0.004). The results of univariate analysis showed that radiotherapy ( χ2 = 7.112, P = 0.008) and concurrent chemoradiotherapy ( χ2 = 10.940, P = 0.004) were the main factors affecting the prognosis. Conclusions:Lymph node and distant metastasis could occur in esophageal carcinoma patients with stage T 1 and T 2. Radiotherapy can prolong the progression-free survival time and concurrent chemoradiotherapy could benefit overall survival of these patients.

The status of lymph node metastasis is an important prognostic factor for many malignant tumors, including lung cancer. In the 8th edition of the TNM staging system for lung cancer, the T staging had obvious changes and refinements, but the N staging had little changes. Recently, several studies have found that the prognosis of patients with the same N stage can vary greatly, suggesting that a more detailed subgroup of patients with the same N stage should be subdivided, including the inclusion of extra-capsular lymph node metastases (ENE). In this review, we reviewed the definition, classification/grading, imaging diagnosis, pathological diagnosis, related molecular markers and their relationship with the prognosis of lung cancer patients.

Objective: To explore the influence of nursing intervention on bone health of breast cancer patients in aromatase inhibitors (AIs) treatment. Methods: Totally 120 breast cancer patients receiving AIs treatment were randomly divided into the observation group (60 cases) and the control group (60 cases), and bone mineral density was measured. After that, the control group was routinely instructed to take calcium supplements, given health lectures, and real-time management. The observation group were given whole-process bone health management intervention based on "Internet+" on the basis of routine nursing. After 1 year, osteoporosis knowledge questionnaire and bone mineral density test were conducted in the two groups. Results: Score of Osteoporosis Knowledge Test of observation group was 21.38±3.29, and 12.54±5.03 of control group, comparing the two groups was statistically significant (t=10.27, P < 0.05); before intervention bone mineral density of observation group was (1.042±0.138) g/cm², and (1.058±0.127) g/cm² of control group, comparing the two groups has no statistical significance, comparable (t=1.053, P > 0.05); after intervention the bone mineral density of observation group was (0.951±0.108) g/cm², and (0.854±0.100) g/cm² of control group, the comparison between the two groups was statistically significant (t=5.937, P<0.05). After intervention, the incidence of osteoporosis in the observation group was 21.67% (13/60), which was significantly higher than 35.00% (21/60) in the control group (χ²=4.279, P<0.05). Conclusion Whole-course nursing intervention can promote bone health of AIs patients with breast cancer.